Business Description
UroGen Pharma Ltd
SIC : 2834
ISIN : IL0011407140
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.67 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -2.45 | |||||
Debt-to-EBITDA | -1.15 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.77 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 74.3 | |||||
3-Year EBITDA Growth Rate | 20.8 | |||||
3-Year EPS without NRI Growth Rate | 20.5 | |||||
3-Year FCF Growth Rate | 18.6 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.95 | |||||
9-Day RSI | 41.86 | |||||
14-Day RSI | 42.85 | |||||
6-1 Month Momentum % | 3.28 | |||||
12-1 Month Momentum % | 29.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.47 | |||||
Quick Ratio | 7.2 | |||||
Cash Ratio | 6.23 | |||||
Days Inventory | 234.72 | |||||
Days Sales Outstanding | 61 | |||||
Days Payable | 235.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -14.19 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.53 | |||||
Operating Margin % | -82.12 | |||||
Net Margin % | -123.74 | |||||
FCF Margin % | -97.8 | |||||
ROA % | -66.8 | |||||
ROIC % | -261.22 | |||||
ROC (Joel Greenblatt) % | -1013.61 | |||||
ROCE % | -67.2 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.78 | |||||
EV-to-EBIT | -4.73 | |||||
EV-to-EBITDA | -4.82 | |||||
EV-to-Revenue | 4.87 | |||||
EV-to-Forward-Revenue | 4.3 | |||||
EV-to-FCF | -4.98 | |||||
Earnings Yield (Greenblatt) % | -21.13 | |||||
FCF Yield % | -17.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
UroGen Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 77.905 | ||
EPS (TTM) (€) | -3.085 | ||
Beta | 2.78 | ||
Volatility % | 128.39 | ||
14-Day RSI | 42.85 | ||
14-Day ATR (€) | 0.258826 | ||
20-Day SMA (€) | 11.895 | ||
12-1 Month Momentum % | 29.23 | ||
52-Week Range (€) | 7.75 - 21.2 | ||
Shares Outstanding (Mil) | 36.13 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
UroGen Pharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
UroGen Pharma Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
UroGen Pharma Ltd Frequently Asked Questions
What is UroGen Pharma Ltd(STU:UR8)'s stock price today?
When is next earnings date of UroGen Pharma Ltd(STU:UR8)?
Does UroGen Pharma Ltd(STU:UR8) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |